Bladder and bowel dysfunction in Parkinson's disease

被引:144
作者
Sakakibara, R. [1 ,2 ]
Uchiyama, T. [2 ]
Yamanishi, T. [3 ]
Shirai, K. [1 ]
Hattori, T. [2 ]
机构
[1] Toho Univ, Div Neurol, Sakura Med Ctr, Dept Internal Med, 564-1 Shimoshizu, Sakura, Ibaraki 2858741, Japan
[2] Chiba Univ, Dept Neurol, Chiba, Japan
[3] Dokkyo Med Coll, Dept Urol, Mibu, Tochigi, Japan
关键词
Parkinson's disease; bladder dysfunction; bowel dysfunction; autonomic nervous system; dopamine;
D O I
10.1007/s00702-007-0855-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Bladder dysfunction (urinary urgency/frequency) and bowel dysfunction (constipation) are common non-motor disorders in Parkinson's disease (PD). In contrast to motor disorder, the pelvic autonomic dysfunction is often non-responsive to levodopa treatment. Brain pathology mostly accounts for the bladder dysfunction (appearance of overactivity) via altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. In contrast, peripheral enteric pathology mostly accounts for the bowel dysfunction (slow transit and decreased phasic contraction) via altered dopamine-enteric nervous system circuit, which normally promotes the peristaltic reflex. In addition, weak strain and paradoxical anal contraction might be the results of brain pathology. Pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore it might aid the differential diagnosis. Drugs to treat bladder dysfunction in PD include anticholinergic agents. Drugs to treat bowel dysfunction in PD include dietary fibers, peripheral dopaminergic antagonists, and selective serotonergic agonists. These treatments might be beneficial not only in maximizing patients' quality of life, but also in promoting intestinal absorption of levodopa and avoiding gastrointestinal emergency.
引用
收藏
页码:443 / 460
页数:18
相关论文
共 208 条
[1]   Frequency of bowel movements and the future risk of Parkinson's disease [J].
Abbott, RD ;
Petrovitch, H ;
White, LR ;
Masaki, KH ;
Tanner, CM ;
Curb, JD ;
Grandinetti, A ;
Blanchette, PL ;
Popper, JS ;
Ross, GW .
NEUROLOGY, 2001, 57 (03) :456-462
[2]  
Abrams P, 2002, NEUROUROL URODYNAM, V21, P167, DOI 10.1002/nau.10052
[3]   Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder [J].
Abrams, Paul ;
Andersson, Karl-Erik ;
Buccafusco, Jerry J. ;
Chapple, Christopher ;
de Groat, William Chet ;
Fryer, Alison D. ;
Kay, Gary ;
Laties, Alan ;
Nathanson, Neil M. ;
Pasricha, Pankaj Jay ;
Wein, Alan J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (05) :565-578
[4]   Severe constipation in Parkinson's disease relieved by botulinum toxin [J].
Albanese, A ;
Maria, G ;
Bentivoglio, A ;
Brisinda, G ;
Cassetta, E ;
Tonali, P .
MOVEMENT DISORDERS, 1997, 12 (05) :764-766
[5]   Mechanisms of disease: Central nervous system involvement in overactive bladder syndrome [J].
Andersson, Karl-Erik .
NATURE CLINICAL PRACTICE UROLOGY, 2004, 1 (02) :103-108
[6]   Treatment of overactive bladder: Other drug mechanisms [J].
Andersson, KE .
UROLOGY, 2000, 55 (5A) :51-57
[7]   Chemical coding of the human gastrointestinal nervous system:: Cholinergic, VIPergic, and catecholaminergic phenotypes [J].
Anlauf, M ;
Schäfer, MKH ;
Eiden, L ;
Weihe, E .
JOURNAL OF COMPARATIVE NEUROLOGY, 2003, 459 (01) :90-111
[8]   Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score [J].
Araki, I ;
Kuno, S .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2000, 68 (04) :429-433
[9]   Voiding dysfunction and Parkinson's disease: Urodynamic abnormalities and urinary symptoms [J].
Araki, I ;
Kitahara, M ;
Oida, T ;
Kuno, S .
JOURNAL OF UROLOGY, 2000, 164 (05) :1640-1643
[10]   EFFECTS OF APOMORPHINE AND L-DOPA ON THE PARKINSONIAN BLADDER [J].
ARANDA, B ;
CRAMER, P .
NEUROUROLOGY AND URODYNAMICS, 1993, 12 (03) :203-209